Solomon Moshkevich Sells 1,026 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,026 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04. Following the completion of the transaction, the insider now directly owns 144,782 shares of the company’s stock, valued at approximately $21,143,963.28. This represents a 0.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Stock Down 0.8 %

Shares of NASDAQ NTRA opened at $149.63 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The firm has a market capitalization of $20.23 billion, a PE ratio of -85.02 and a beta of 1.80. The firm has a fifty day simple moving average of $161.71 and a two-hundred day simple moving average of $149.27.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research reports. Royal Bank of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price objective for the company. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Morgan Stanley upped their price objective on shares of Natera from $176.00 to $185.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, Robert W. Baird upped their price objective on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.12.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Principal Securities Inc. increased its stake in shares of Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC increased its stake in shares of Natera by 1.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after acquiring an additional 61 shares in the last quarter. Silver Oak Securities Incorporated increased its stake in shares of Natera by 3.1% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after acquiring an additional 89 shares in the last quarter. Colonial Trust Co SC increased its stake in shares of Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company’s stock worth $210,000 after acquiring an additional 96 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.